Wegovy and alcohol dependence are now linked by a new Danish clinical study, which found that people treated with semaglutide drank less, had more alcohol-free days and reported weaker cravings after six months. The trial, carried out by researchers at the Mental Health Centre Copenhagen (Psykiatrisk Center København) at Bispebjerg-Frederiksberg Hospital, adds to growing evidence that GLP-1 drugs may affect not only appetite and weight, but also reward mechanisms involved in addiction.
Wegovy and alcohol dependence were tested in a Danish trial
The study focused on 108 adults with alcohol use disorder and severe obesity. Over a period of 26 weeks, one group received semaglutide, the active substance in Wegovy and Ozempic, while another group received a placebo. Participants also took part in treatment designed to help reduce alcohol intake, an important factor when interpreting the results.
Researchers found that those given semaglutide reduced their drinking more than those in the placebo group. According to the figures reported by Danish broadcaster TV 2, people receiving semaglutide went from an average of 17 heavy drinking days per month to five. In the placebo group, the number fell to nine days per month.
In the study, a heavy drinking day was defined as a day with at least five alcoholic drinks for men and four for women. Participants treated with semaglutide also drank less overall, recorded more days without alcohol and experienced less craving.
Mette Kruse Klausen, first author of the study, said the findings may matter for a group of patients with a high health burden. “This is a patient group with a high burden of disease and a high risk of both physical and mental complications. If we can reduce the most harmful drinking patterns, it could have great significance for the individual,” she said.
Semaglutide may act on the brain’s reward system
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists. These medicines mimic a hormone involved in satiety and blood sugar regulation, helping people feel full and reducing appetite. Wegovy is authorised in Europe for weight management in people with obesity, or in people who are overweight and have weight-related health conditions.
The Danish study suggests that the same biological pathways may also influence the desire to drink alcohol. Researchers believe the effect may involve the brain’s reward system, which is central to addiction, but the exact mechanism remains uncertain.
That uncertainty is important. The study does not show that Wegovy is ready to be prescribed as a treatment for alcohol dependence. It shows that semaglutide may reduce harmful drinking among people who have both alcohol use disorder and obesity, under controlled trial conditions and alongside therapy.
This distinction matters because GLP-1 drugs are already widely discussed as treatments with possible benefits beyond weight loss, from cardiovascular risk reduction to addiction-related behaviour. The Danish findings strengthen that debate, but they do not settle it.
Why the alcohol study is promising but limited
The trial is significant because it was randomised, placebo-controlled and double-blinded, the type of design used to test whether a treatment has a measurable effect beyond expectation, behavioural change or other forms of support.
At the same time, the study was relatively small. It involved 108 participants and lasted six months. It also focused specifically on people with obesity, meaning the results cannot automatically be extended to all people with alcohol dependence.
Another limitation is the lack of long-term follow-up after the treatment period. It remains unclear whether reduced drinking continues after semaglutide is stopped, whether patients need continued treatment to maintain the effect, and how the balance between benefits, side effects and cost would look in ordinary healthcare systems.
The placebo group also reduced its drinking, probably because all participants received structured support. This does not weaken the study, but it shows that medication alone is not the full picture. For alcohol dependence, effective treatment often combines medical, psychological and social support.
A wider Nordic and European public health question
The findings come at a time when alcohol remains a major public health issue in Europe. The WHO Regional Office for Europe has described alcohol as a toxic, psychoactive and dependence-producing substance, and estimates that about 800,000 deaths each year in the region are linked to alcohol use.
In Denmark, alcohol consumption has long been part of a broader health debate, especially around binge drinking and young adults. Recent Nordic monitoring data show that binge drinking remains comparatively common among younger Danes, even as some indicators of alcohol consumption have improved over time.
For Nordic health systems, the study raises a practical question: whether medicines originally developed for metabolic disease could become part of future addiction treatment. That would be especially relevant for patients whose alcohol dependence is combined with obesity, liver risk, diabetes risk or other weight-related conditions.
But it also raises policy questions. GLP-1 drugs such as Wegovy are expensive and already subject to debates over access, reimbursement and supply. If future trials confirm an effect on alcohol dependence, governments and health authorities would need to decide who should receive treatment, under what criteria and as part of which care pathway.
Larger trials are needed before clinical use
For now, the Danish results should be read as a strong early signal rather than a change in medical practice. Before Wegovy or other semaglutide-based medicines can be approved for alcohol dependence treatment, researchers need larger phase 3 trials with more participants, more diverse patient groups and longer follow-up.
Mette Kruse Klausen described the findings as an encouraging step, while stressing that the path to a new treatment remains long. “There is still a long way to go, but this is a very good step on the way,” she said.
The study’s importance lies in that balance. It suggests that semaglutide may reduce some of the most harmful patterns of alcohol use, but it also confirms that addiction treatment cannot be reduced to a single drug. For Denmark and the wider Nordic region, the next question is whether this early clinical signal can become a safe, accessible and evidence-based treatment option.
